An active new formulation of iron carried by aspartyl casein for iron-deficiency anemia: results of the ACCESS trial.
Study Goal
The researchers aimed to compare the efficacy and safety of a new oral iron formulation conjugated with N-aspartyl-casein (Fe-ASP) versus ferrous sulfate in treating iron-deficiency anemia.
Results Summary
The study compared Fe-ASP with ferrous sulfate over 12 weeks but did not report specific outcomes regarding Casein's effects in the abstract.
Population
60 patients with iron-deficiency anemia.
Effective Dosage
Twice daily (specific amount not provided).
Duration
12 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Oral iron supplementation | neutral | iron-deficiency anemia | - | - | is the cornerstone for the management | #1 |
A new oral formulation of iron conjugated with N-aspartyl-casein (Fe-ASP) (Omalin®, Uni-Pharma) | neutral | - | 60 patients | - | is studied | #2 |
oral ferrous sulfate (FeSO4) | neutral | - | 60 patients | - | - | #3 |
Oral iron supplementation is the cornerstone for the management of iron-deficiency anemia. A new oral formulation of iron conjugated with N-aspartyl-casein (Fe-ASP) (Omalin®, Uni-Pharma) is studied in the ACCESS double-blind, double-dummy randomized clinical trial; 60 patients were randomized to 12-week oral treatment twice every day either with oral ferrous sulfate (FeSO